Close Menu

NEW YORK – Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, and OraSure Technologies subsidiary CoreBiome said on Tuesday that they are collaborating to develop a colon cancer screening test.

The test, called LifeKit Prevent, will use microbial biomarkers to predict the development of precancerous adenomas and carcinomas. The companies said they will use shotgun metagenomic sequencing, machine learning, and AI-driven microbiome analytics to accelerate their development pipeline. 

Financial terms of the collaboration were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.